Ireland· IE-PA-EU/1/17/1231/001-002
Ocrevus 300 mg concentrate for solution for infusion
A ocrelizumab product containing ocrelizumab, registered in Ireland by Roche Registration GmbH.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Ocrelizumab
- Manufacturer
- Roche Registration GmbH
- Country
- Ireland (IE)
- ATC code
- L04AA36
- ATC class
- Ocrelizumab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/17/1231/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
328 interactions on record for ocrelizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ocrelizumab · interactions on record
328 records
- 27 severe
- 294 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- PrednisoloneA07EA01moderate
- HydrocortisoneA07EA02moderate
- PrednisoneA07EA03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ocrelizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandOcrevusParanova Oy
- CzechiaOCREVUSRoche Registration GmbH, Grenzach-Wyhlen
- BelgiumOcrevus 300 mgRoche Registration
- IcelandOcrevusRoche Registration GmbH*
- NetherlandsOcrevus 300 mg concentraat voor oplossing voor infusieRoche Registration GmbH
- SwedenOcrevus 300 mg Koncentrat till infusionsvätska, lösningRoche Registration GmbH
- United KingdomOcrevus 300mg/10ml concentrate for solution for infusion vialsRoche Products Ltd
- FranceOCREVUS 300 mg, solution à diluer pour perfusionROCHE REGISTRATION (ALLEMAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ocrevus
- Liechtenstein · Ocrevus
- Norway · Ocrevus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9909e027-646f-432c-a406-5816e9104c54 GET /v1/drugs/9909e027-646f-432c-a406-5816e9104c54?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L04AA",
"L04AA36"
],
"strength": null,
"pa_number": "EU/1/17/1231/001-002",
"substances": [
"Ocrelizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about ocrelizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.